Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 4Neoplasm Metastasis 3Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1HTLV-I Infections 1Colorectal Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 20Carboplatin 14Cyclophosphamide 12atezolizumab 11Paclitaxel 10Albumin-Bound Paclitaxel 8Capecitabine 7Nivolumab 6130-nm albumin-bound paclitaxel 6spartalizumab 5fludarabine 5Taxes 5Gemcitabine 5talazoparib 4bintrafusp alfa protein, human 4avelumab 4Cisplatin 4sacituzumab govitecan 3olaparib 3entinostat 3Leucovorin 3Ipilimumab 3Immunoglobulin G 3Drug Therapy 3Doxorubicin 3Docetaxel 3Biopsy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3trilaciclib 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Triple Negative Breast Neoplasms × Interferon alpha-2 × Clear all
NCT05756166 2025-06-24

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 1/2 Terminated
5 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡